Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2017 4
2018 9
2019 11
2020 10
2021 13
2022 13
2023 15
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review.
Prelaj A, Miskovic V, Zanitti M, Trovo F, Genova C, Viscardi G, Rebuzzi SE, Mazzeo L, Provenzano L, Kosta S, Favali M, Spagnoletti A, Castelo-Branco L, Dolezal J, Pearson AT, Lo Russo G, Proto C, Ganzinelli M, Giani C, Ambrosini E, Turajlic S, Au L, Koopman M, Delaloge S, Kather JN, de Braud F, Garassino MC, Pentheroudakis G, Spencer C, Pedrocchi ALG. Prelaj A, et al. Ann Oncol. 2024 Jan;35(1):29-65. doi: 10.1016/j.annonc.2023.10.125. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879443 Review.
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Camidge DR, Lin JJ, Kim SW, Solomon BJ, Dziadziuszko R, Besse B, Goto K, de Langen AJ, Wolf J, Lee KH, Popat S, Springfeld C, Nagasaka M, Felip E, Yang N, Velcheti V, Lu S, Kao S, Dooms C, Krebs MG, Yao W, Beg MS, Hu X, Moro-Sibilot D, Cheema P, Stopatschinskaja S, Mehta M, Trone D, Graber A, Sims G, Yuan Y, Cho BC; TRIDENT-1 Investigators. Drilon A, et al. N Engl J Med. 2024 Jan 11;390(2):118-131. doi: 10.1056/NEJMoa2302299. N Engl J Med. 2024. PMID: 38197815 Clinical Trial.
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. Proto C, et al. Among authors: prelaj a. J Thorac Oncol. 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009. Epub 2023 Apr 23. J Thorac Oncol. 2023. PMID: 37094664 Clinical Trial.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
Lo Russo G, Prelaj A, Dolezal J, Beninato T, Agnelli L, Triulzi T, Fabbri A, Lorenzini D, Ferrara R, Brambilla M, Occhipinti M, Mazzeo L, Provenzano L, Spagnoletti A, Viscardi G, Sgambelluri F, Brich S, Miskovic V, Pedrocchi ALG, Trovo' F, Manglaviti S, Giani C, Ambrosini P, Leporati R, Franza A, McCulloch J, Torelli T, Anichini A, Mortarini R, Trinchieri G, Pruneri G, Torri V, De Braud F, Proto C, Ganzinelli M, Garassino MC. Lo Russo G, et al. Among authors: prelaj a. J Immunother Cancer. 2023 Jun;11(6):e006833. doi: 10.1136/jitc-2023-006833. J Immunother Cancer. 2023. PMID: 37286305 Free PMC article. Clinical Trial.
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).
Cornelissen R, Prelaj A, Sun S, Baik C, Wollner M, Haura EB, Mamdani H, Riess JW, Cappuzzo F, Garassino MC, Heymach JV, Socinski MA, Leu SY, Bhat G, Lebel F, Le X; ZENITH20-4 Investigators. Cornelissen R, et al. Among authors: prelaj a. J Thorac Oncol. 2023 Aug;18(8):1031-1041. doi: 10.1016/j.jtho.2023.03.016. Epub 2023 Mar 21. J Thorac Oncol. 2023. PMID: 36958688 Clinical Trial.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Viscardi G, et al. Among authors: prelaj a. Eur J Cancer. 2022 Dec;177:175-185. doi: 10.1016/j.ejca.2022.09.031. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36368251 Review.
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.
Prelaj A, Ganzinelli M, Trovo' F, Roisman LC, Pedrocchi ALG, Kosta S, Restelli M, Ambrosini E, Broggini M, Pravettoni G, Monzani D, Nuara A, Amat R, Spathas N, Willis M, Pearson A, Dolezal J, Mazzeo L, Sangaletti S, Correa AM, Aguaron A, Watermann I, Popa C, Raimondi G, Triulzi T, Steurer S, Lo Russo G, Linardou H, Peled N, Felip E, Reck M, Garassino MC. Prelaj A, et al. Clin Lung Cancer. 2023 Jun;24(4):381-387. doi: 10.1016/j.cllc.2023.02.005. Epub 2023 Feb 28. Clin Lung Cancer. 2023. PMID: 36959048
Exploring the role of respiratory microbiome in lung cancer: A systematic review.
Perrone F, Belluomini L, Mazzotta M, Bianconi M, Di Noia V, Meacci F, Montrone M, Pignataro D, Prelaj A, Rinaldi S, Russano M, Sartori G, Bironzo P, Facchinetti F, Menis J, Tiseo M, Galetta D, Novello S, Pilotto S. Perrone F, et al. Among authors: prelaj a. Crit Rev Oncol Hematol. 2021 Aug;164:103404. doi: 10.1016/j.critrevonc.2021.103404. Epub 2021 Jun 29. Crit Rev Oncol Hematol. 2021. PMID: 34214609 Review.
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
De Toma A, Lo Russo G, Signorelli D, Pagani F, Randon G, Galli G, Prelaj A, Ferrara R, Proto C, Ganzinelli M, Zilembo N, de Braud F, Garassino MC. De Toma A, et al. Among authors: prelaj a. Crit Rev Oncol Hematol. 2021 Apr;160:103299. doi: 10.1016/j.critrevonc.2021.103299. Epub 2021 Mar 16. Crit Rev Oncol Hematol. 2021. PMID: 33722699 Free article. Review.
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG, Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall PS, Dienstmann R, Booth CM, Pentheroudakis G, Delaloge S, Koopman M. Castelo-Branco L, et al. Among authors: prelaj a. Ann Oncol. 2023 Dec;34(12):1097-1112. doi: 10.1016/j.annonc.2023.10.001. Epub 2023 Oct 15. Ann Oncol. 2023. PMID: 37848160 No abstract available.
72 results